المؤلفون: A. A. Spasov, O. N. Zhukovskaya, A. I. Rashchenko, A. A. Brigadirova, R. A. Litvinov, N. A. Gurova, A. V. Smirnov, N. G. Pan’shin, H. S.A. Abbas, A. S. Morkovnik, А. А. Спасов, О. Н. Жуковская, А. И. Ращенко, А. А. Бригадирова, Р. А. Литвинов, Н. А. Гурова, А. В. Смирнов, Н. Г. Паньшин, Х. С.А. Аббас, А. С. Морковник

المساهمون: The chemical part of this work was carried out in the Institute of Organic and Physical Chemistry, Southern Federal University with a financial support by the Ministry of Science and Higher Education of the Russian Federation in the framework of the state task, grant FENW-2020-0031 (0852-2020-0031). The biological part of this work was financially supported by the Russian Science Foundation (Project 14-25-00139)., Химическая часть исследования выполнена в Институте органической и физической химии ФГАОУ ВПО «Южный федеральный университет» при финансовой поддержке Министерства науки и высшего образования Российской Федерации в рамках государственного задания, грант ФЕНВ-2020-0031 (0852-2020-0031). Биологическая часть исследования проведена при финансовой поддержке Российского научного фонда (проект 14-25-00139).

المصدر: Pharmacy & Pharmacology; Том 10, № 6 (2022); 549-561 ; Фармация и фармакология; Том 10, № 6 (2022); 549-561 ; 2413-2241 ; 2307-9266 ; 10.19163/2307-9266-2022-10-6

مصطلحات موضوعية: стрептозотоцин-индуцированный диабет, cross-links, ALT-711 (alagebrium), diabetes mellitus, diabetic kidney disease (nephropathy), streptozotocin-induced diabetes, поперечные сшивки, ALT-711 (алагебриум), сахарный диабет, диабетическая болезнь почек (нефропатия)

وصف الملف: application/pdf

Relation: https://www.pharmpharm.ru/jour/article/view/1220/931; https://www.pharmpharm.ru/jour/article/view/1220/932; Silva J.A.D., Souza E.C.F., Echazú Böschemeier A.G., Costa C.C.M.D., Bezerra H.S., Feitosa E.E.L.C. Diagnosis of diabetes mellitus and living with a chronic condition: participatory study // BMC Public Health. – 2018. – Vol. 18, No. 1. – Art. ID: 699. DOI:10.1186/s12889-018-5637-9; Singh V.P., Bali A., Singh N., Jaggi A.S. Advanced Glycation End Products and Diabetic Complications // Korean J. Physiol. Pharmacol. – 2014. – Vol. 18, No. 1. – P. 1–14. DOI:10.4196/kjpp.2014.18.1.1; Rhee S.Y., Kim Y.S. The Role of Advanced Glycation End Products in Diabetic Vascular Complications // Diabetes Metab. J. – 2018. – Vol. 42, No. 3. – P. 188–195. DOI:10.4093/dmj.2017.0105; Chaudhuri J., Bains Y., Guha S., Kahn A., Hall D., Bose N., et al. The Role of Advanced Glycation End Products in Aging and Metabolic Diseases: Bridging Association and Causality // Cell Metab. – 2018. – Vol .28, No. 3. – P. 337–352. DOI:10.1016/j.cmet.2018.08.014; Bodiga V.L., Eda S.R., Bodiga S. Advanced glycation end products: role in pathology of diabetic cardiomyopathy // Heart Fail Rev. – 2014. – Vol. 19, No. 1. – P. 49–63. DOI:10.1007/s10741-013-9374-y; Bhat S., Mary S., Giri A.P., Kulkarni M.J. Advanced Glycation End Products (AGEs) in Diabetic Complications / Mechanisms of Vascular Defects in Diabetes Mellitus. Advances in Biochemistry in Health and Disease // Edited by Kartha C.C., Ramachandran S., Pillai R.M. Cham: Springer International Publishing, 2017. – P. 423–449. DOI:10.1007/978-3-319-60324-7_19; Rabbani N., Thornalley P.J. Advanced glycation end products in the pathogenesis of chronic kidney disease // Kidney Int. – 2018. – Vol. 93, No. 4 – P. 803–813. DOI:10.1016/j.kint.2017.11.034; Nabi R., Alvi S.S., Saeed M., Ahmad S., Khan M.S. Glycation and HMG-CoA Reductase Inhibitors: Implication in Diabetes and Associated Complications // Curr. Diabetes Rev. – 2019. – Vol. 15, No. 3. – P. 213–223. DOI:10.2174/1573399814666180924113442; Nabi R., Alvi S.S., Khan R.H., Ahmad S., Ahmad S., Khan M.S. Antiglycation study of HMG-R inhibitors and tocotrienol against glycated BSA and LDL: A comparative study // Int. J. Biol. Macromol. – 2018. – Vol. 116. – P. 983–992. DOI:10.1016/j.ijbiomac.2018.05.115; Rahbar S., Figarola J.L. Novel inhibitors of advanced glycation endproducts // Arch. Biochem. Biophys. – 2003. – Vol. 419, No. 1. – P. 63–79. DOI:10.1016/j.abb.2003.08.009; Akhter F., Khan M.S., Ahmad S. Acquired immunogenicity of calf thymus DNA and LDL modified by D-ribose: a comparative study // Int. J. Biol. Macromol. – 2015. – Vol. 72. – P. 1222–1227. DOI:10.1016/j.ijbiomac.2014.10.034; Jabir N.R., Ahmad S., Tabrez S. An insight on the association of glycation with hepatocellular carcinoma // Semin. Cancer. Biol. – 2018. – Vol. 49. – P. 56–63. DOI:10.1016/j.semcancer.2017.06.005; Brings S., Fleming T., Freichel M., Muckenthaler M.U., Herzig S., Nawroth P.P. Dicarbonyls and Advanced Glycation End-Products in the Development of Diabetic Complications and Targets for Intervention // Int. J. Mol. Sci. – 2017. – Vol. 18, No. 5. – Art. ID: 984. DOI:10.3390/ijms18050984; Vasan S., Foiles P., Founds H. Therapeutic potential of breakers of advanced glycation end product–protein crosslinks // Arch. Biochem. Biophys. – 2003. – Vol. 419, No. 1. – P. 89–96. DOI:10.1016/j.abb.2003.08.016; Zuehlke C.W. Methods of Organic Elemental Microanalysis // J. Am. Chem. Soc. – 1963. – Vol. 85, No. 16. – Art. ID: 2536. DOI:10.1021/ja00899a055; Vasan S., Zhang X., Zhang X., Kapurniotu A., Bernhagen J., Teichberg S., Basgen J., Wagle D., Shih D., Terlecky I., Bucala R., Cerami A., Egan J., Ulrich P. An agent cleaving glucose-derived protein crosslinks in vitro and in vivo // Nature. – 1996. – Vol. 382, No. 6588. – P. 275–278. DOI:10.1038/382275a0; Жуковская О.Н., Анисимова В.А., Морковник А.С., Петров В.И., Спасов А.А., Ращенко А.И., Бригадирова А.А., Аббас Х.С.А. 9-бензил-2-бифенилимидазо[1,2-а]бензимидазол и его фармацевтически приемлемые соли, проявляющие свойства разрушителей поперечных сшивок гликированных белков. RU 2627769 C1, 2017.; Zhang B., He K., Chen W., Cheng X., Cui H., Zhong W., Li S., Wang L. Alagebrium (ALT-711) improves the anti-hypertensive efficacy of nifedipine in diabetic-hypertensive rats // Hypertens. Res. – 2014. – Vol. 37, No. 10. – P. 901–907. DOI:10.1038/hr.2014.98; Cheng G., Wang L.L., Qu W.S., Long L., Cui H., Liu H.Y., Cao Y.L., Li S. C16, a novel advanced glycation endproduct breaker, restores cardiovascular dysfunction in experimental diabetic rats // Acta Pharmacol. Sin. – 2005. – Vol. 26, No. 12. – P. 1460–1466. DOI:10.1111/j.1745-7254.2005.00240.x; Cheng G., Wang L.L., Long L., Liu H.Y., Cui H., Qu W.S., Li S. Beneficial effects of C36, a novel breaker of advanced glycation endproducts cross-links, on the cardiovascular system of diabetic rats // Br. J. Pharmacol. – 2007. – Vol. 152, No. 8. – P. 1196–1206. DOI:10.1038/sj.bjp.0707533; Spasov A.A., Zhukovskaya O.N., Brigadirova A.A., Abbas H.S.A., Anisimova V.A., Sysoeva V.A., Rashchenko A.I., Litvinov R.A., Mayka O.Yu., Babkov D.A., Morkovnik A.S. Synthesis and pharmacological activity of 2-(biphenyl-4-yl)imidazo[1,2-a]benzimidazoles // Russ. Chem. Bull. – 2017. – Vol. 66. – P. 1905–1912. DOI:10.1007/s11172-017-1965-7; Cho S.J., Roman G., Yeboah F., Konishi Y. The Road to Advanced Glycation End Products: A Mechanistic Perspective // Curr. Med. Chem. – 2007. – Vol. 14, No. 15. – P. 1653–1671. DOI:10.2174/092986707780830989; Tang S.C.W., Yiu W.H. Innate immunity in diabetic kidney disease // Nat. Rev. Nephrol. 2020- Vol. 16. – P. 206–222. DOI:10.1038/s41581-019-0234-4; Yao D., Wang S., Wang M., Lu W. Renoprotection of dapagliflozin in human renal proximal tubular cells via the inhibition of the high mobility group box 1receptor for advanced glycation end productsnuclear factorκB signaling pathway // Mol. Med. Rep. – 2018. – Vol. 18, No. 4. – P. 3625–3630. DOI:10.3892/mmr.2018.9393.; Kolset S.O., Reinholt F.P., Jenssen T. Diabetic Nephropathy and Extracellular Matrix // J. Histochem. Cytochem. – 2012. – Vol. 60, No. 12. – P. 976–986. DOI:10.1369/0022155412465073; Dalla Vestra M., Saller A., Mauer M., Fioretto P. Role of mesangial expansion in the pathogenesis of diabetic nephropathy // J. Nephrol. – 2001. – Vol. 14, Suppl 4. – P. 51–57.; Amorim R.G., Guedes G. da S., Vasconcelos S.M. de L., Santos J.C. de F. Kidney Disease in Diabetes Mellitus: Cross-Linking between Hyperglycemia, Redox Imbalance and Inflammation // Arq. Bras. Cardiol. – 2019. – Vol. 112, No. 5. – P. 577-587. DOI:10.5935/abc.20190077. Erratum in: Arq. Bras. Cardiol. – 2019. – Vol. 113, No. 1. – Art. ID: 182.; Vasan S., Foiles P.G., Founds H.W. Therapeutic potential of AGE inhibitors and breakers of AGE protein cross-links // Expert Opin. Investig. Drugs. – 2001. – Vol. 10, No. 11. – P. 1977–1987. DOI:10.1517/13543784.10.11.1977; Forbes J.M., Thallas V., Thomas M.C., Founds H.W., Burns W.C., Jerums G., Cooper ME. The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes // FASEB J. – 2003. – Vol. 17, No. 12. – P. 1762–1764. DOI:10.1096/fj.02-1102fje; Kim Y.S., Kim J., Kim C.S., Sohn E.J., Lee Y.M., Jeong I.H., Kim H., Jang D.S., Kim J.S. KIOM-79, an Inhibitor of AGEs–Protein Cross-linking, Prevents Progression of Nephropathy in Zucker Diabetic Fatty Rats // Evid. Based Complement. Alternat. Med. – 2011. – Vol. 2011. – P. 1–10. DOI:10.1093/ecam/nep078; Jung E., Park S.B., Jung W.K., Kim H.R., Kim J. Antiglycation Activity of Aucubin In Vitro and in Exogenous Methylglyoxal Injected Rats // Molecules. – 2019. – Vol. 24, No. 20. – Art. ID: 3653. DOI:10.3390/molecules24203653; Kim J., Kim C.S., Kim Y.S., Lee I.S., Kim J.S. Jakyakgamcho-tang and Its Major Component, Paeonia Lactiflora, Exhibit Potent Anti-glycation Properties // J. Exerc. Nutrition Biochem. – 2016. – Vol. 20, No. 4. – P. 60–64. DOI:10.20463/jenb.2016.0049; Kim C.S., Jo K., Pyo M.K., Kim J.S., Kim J. Pectin lyase-modified red ginseng extract exhibits potent anti-glycation effects in vitro and in vivo // J. Exerc. Nutrition Biochem. – 2017. – Vol. 21, No. 2. – P. 56–62. DOI:10.20463/jenb.2017.0011; Coughlan M.T., Forbes J.M., Cooper M.E. Role of the AGE crosslink breaker, alagebrium, as a renoprotective agent in diabetes // Kidney International. – 2007. – Vol. 72, Suppl. 106. – P. 54–60. DOI:10.1038/sj.ki.5002387; Thallas-Bonke V., Lindschau C., Rizkalla B., Bach L.A., Boner G., Meier M., Haller H., Cooper M.E., Forbes J.M. Attenuation of Extracellular Matrix Accumulation in Diabetic Nephropathy by the Advanced Glycation End Product Cross-Link Breaker ALT-711 via a Protein Kinase C- -Dependent Pathway // Diabetes. – 2004. – Vol. 53. – P. 2921–2930. DOI:10.2337/diabetes.53.11.2921; Yang S., Litchfield J.E., Baynes J.W. AGE-breakers cleave model compounds, but do not break Maillard crosslinks in skin and tail collagen from diabetic rats // Arch. Biochem. Biophys. – 2003. – Vol. 412, No. 1. – P. 42–46. DOI:10.1016/S0003-9861(03)00015-8; Nasiri R., Field M.J., Zahedi M., Moosavi-Movahedi A.A. Cross-Linking Mechanisms of Arginine and Lysine with α,β-Dicarbonyl Compounds in Aqueous Solution // J. Phys. Chem. A. – 2011. – Vol. 115, No. 46. – P. 13542–13555. DOI:10.1021/jp205558d; Nasiri R., Field M.J., Zahedi M., Moosavi-Movahedi A.A. Comparative DFT Study To Determine if α-Oxoaldehydes are Precursors for Pentosidine Formation // J. Phys. Chem. A. – 2012. – Vol. 116, No. 11. – P. 2986–2996. DOI:10.1021/jp2104165; Nobécourt E., Zeng J., Davies M.J., Brown B.E., Yadav S., Barter P.J., Rye K.A. Effects of cross-link breakers, glycation inhibitors and insulin sensitisers on HDL function and the non-enzymatic glycation of apolipoprotein A-I // Diabetologia. – 2008. – Vol. 51, No. 6. – P. 1008–1017. DOI:10.1007/s00125-008-0986-z; Kim T., Spiegel D.A. The Unique Reactivity of N-Phenacyl-Derived Thiazolium Salts Toward α-Dicarbonyl Compounds // Rejuvenation Res. – 2013. – Vol. 16, No. 1. – P. 43–50. DOI:10.1089/rej.2012.1370; Sherwani S.I., Khan H.A., Ekhzaimy A., Masood A., Sakharkar M.K. Significance of HbA1c Test in Diagnosis and Prognosis of Diabetic Patients // Biomark Insights. – 2016. – Vol. 11. – P. 95–104. DOI:10.4137/BMI.S38440; Nagai R., Murray D.B., Metz T.O., Baynes J.W. Chelation: A Fundamental Mechanism of Action of AGE Inhibitors, AGE Breakers, and Other Inhibitors of Diabetes Complications // Diabetes. 2012. – Vol. 61, No. 3. – P. 549–559. DOI:10.2337/db11-1120; Toprak C., Yigitaslan S. Alagebrium and Complications of Diabetes Mellitus // Eurasian J. Med. – 2019. – Vol. 51, No. 3. – P. 285–292. DOI:10.5152/eurasianjmed.2019.18434; https://www.pharmpharm.ru/jour/article/view/1220

الاتاحة: https://www.pharmpharm.ru/jour/article/view/1220
https://doi.org/10.19163/2307-9266-2022-10-6-549-561

المؤلفون: A. A. Spasov, O. N. Zhukovskaya, A. I. Rashchenko, A. A. Brigadirova, R. A. Litvinov, N. A. Gurova, A. V. Smirnov, N. G. Pan’shin, H. S.A. Abbas, A. S. Morkovnik

المصدر: Фармация и фармакология (Пятигорск), Vol 10, Iss 6, Pp 549-561 (2023)

مصطلحات موضوعية: конечные продукты гликирования, поперечные сшивки, alt-711 (алагебриум), сахарный диабет, диабетическая болезнь почек (нефропатия), стрептозотоцин-индуцированный диабет, Therapeutics. Pharmacology, RM1-950

Relation: https://www.pharmpharm.ru/jour/article/view/1220; https://doaj.org/toc/2307-9266; https://doaj.org/toc/2413-2241; https://doaj.org/article/d4d13d12ef394ea1a10e466236f08455

الاتاحة: https://doi.org/10.19163/2307-9266-2022-10-6-549-561
https://doaj.org/article/d4d13d12ef394ea1a10e466236f08455